Phase I Safety and Clinical Activity Study of Thymoquinone in Patients with Advanced Refractory Malignant Disease.
Authors
Ali M. Al-Amri, MD1,*, Abdullah O. Bamosa MBBS, PHD2
1Department of Internal Medicine/Oncology, College of Medicine, King Faisal University, King Fahd Hospital of the University, Al-Khobar, Eastern Province, Kingdom of Saudi Arabia.
2Department of Physiology, College of Medicine, King Faisal University, Dammam, Saudi Arabia.
*Corresponding Author: Department of Internal Medicine and Oncology, King Fahd Hospital of the University, Kingdom of Saudi Arabia, Telephone: +966(3) 8580-107, Fax +966(3) 8966-741, [email protected]. Email: [email protected]
How to Cite:Al-Amri, MD AM, MBBS, PHD AOB. Phase I Safety and Clinical Activity Study of Thymoquinone in Patients with Advanced Refractory Malignant Disease.. Shiraz E-Med J. 2009;10(3):. doi:
Abstract
Purpose:
This phase I study was conducted to determine the general toxicities of thymoquinone
in humans, as well as any anti-cancer effects that the drug may have in patients
with advanced cancer for which there were no standard curative or palliative measures.
Patients and methods:
Adult patients with solid tumors or hematological malignancies who
had failed or relapsed from standard therapy were included in this study.
Patients who were at least 18 years of age with an Eastern cooperative oncology group performance
status (ECOG) of ? 2 received thymoquinone orally at a starting dose level of 3, 7,
or 10mg/kg/day. Dose escalation proceeded according to a modified Fibonacci design.
Results:
All 21 patients received at least one week of treatment, with a median of 3.71
weeks (range 1 week to 20 weeks). No side effects were reported and the maximum tolerated
dose (MDT) was not identified. No anti-cancer effects were observed.
Conclusion:
On the basis of this study, thymoquinone was well tolerated at a dose ranging
from 75mg/day to 2600mg/day. Neither toxicities nor therapeutic responses were reported.
Hemati M, Abdollahi M, Pashaei M, Ghahremanfard F, Kokhaei P. The effect of Thymoquinone on Peripheral Blood Mononuclear Cells (PBMCs) viability of patients with B-Chronic Lymphocytic Leukemia. koomesh. 2023;25(2):e152812. doi:
Ghiaee Shamloo A, Yadegari MH, Roudbar Mohammadi S, Jaafari M, Zarrinfar H. Designing and Synthesis of an Anti-Candida parapsilosis Thymoquinone Lipid Formulation. Jundishapur J Microbiol. 2023;16(10):e141934. doi: https://doi.org/10.5812/jjm-141934
Taherkhani M. In vitro Cytobiological Effects of Phytochemicals from Artemisia turanica. J Rep Pharm Sci. 2019;8(1):e147486. doi: https://doi.org/10.4103/jrptps.jrptps_37_18
Dehghani H, Hashemi M, Entezari M, Mohsenifar A. The Comparison of Anticancer Activity of Thymoquinone and Nanothymoquinone on Human Breast Adenocarcinoma. Iran J Pharm Res. 2015;14(2):e125355. doi: https://doi.org/10.22037/ijpr.2015.1648